Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.

H. G. Katz, Matthew; Shi, Qian; P. Meyers, Jeffrey; M. Herman, Joseph; Choung, Michael; M. Wolpin, Brian; A. Ahmad, Syed; Marsh, Robert; H. Schwartz, Lawrence; C. Behr, Spencer; L. Frankel, Wendy; A. Collisson, Eric; L. Leenstra, James; M. Williams, Terence; M. Vaccaro, Gina; P. Venook, Alan; A. Meyerhardt, Jeffrey; M. O’Reilly, Eileen

doi:10.1200/jco.2021.39.3_suppl.377

Public

Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.

Published in Journal of Clinical Oncology • Jan 20, 2021

Authors:

Matthew H. G. Katz

Qian Shi

Jeffrey P. Meyers

Abstract

377 Background: Neoadjuvant therapy has been associated with a median overall survival (OS) of 18 – 23 months (mo) in patients (pts) with BR pancreatic ductal adenocarcinoma (PDAC). To establish reference regimens to which novel treatments can be compared in future studies, we evaluated neoadjuvant ...

Subject

Medicine

Clinical endpoint

Oxaliplatin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!